Royal Bank of Canada
CLSD

Royal Bank of Canada’s Clearside Biomedical CLSD Stock Holding History

Royal Bank of Canada’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-93
Closed -$1K – 7172
2025
Q2 		$1K Buy
+93
New +$1.15K ﹤0.01% 6860
2024
Q3 		– Sell
-38
Closed -$1K – 6919
2024
Q2 		$1K Buy
+38
New +$734 ﹤0.01% 6795
2024
Q1 		– Sell
-15
Closed – – 7067
2023
Q4 		$0 Sell
15
-2,987
-100% -$42.6K ﹤0.01% 7168
2023
Q3 		$39K Buy
3,002
+2,981
+14,195% +$45.1K ﹤0.01% 5905
2023
Q2 		$0 Buy
21
+20
+2,000% +$344 ﹤0.01% 7299
2023
Q1 		$0 Hold
1
– – ﹤0.01% 7111
2022
Q4 		$0 Sell
1
-16
-94% -$288 ﹤0.01% 7275
2022
Q3 		$0 Buy
+17
New +$372 ﹤0.01% 7485
2022
Q2 		– Sell
-25
Closed -$1K – 7402
2022
Q1 		$1K Sell
25
-43
-63% -$1.29K ﹤0.01% 7578
2021
Q4 		$3K Buy
+68
New +$4.4K ﹤0.01% 7325
2021
Q1 		– Sell
-1
Closed – – 7451
2020
Q4 		$0 Sell
1
-102
-99% -$2.65K ﹤0.01% 7077
2020
Q3 		$3K Buy
103
+2
+2% +$52 ﹤0.01% 6223
2020
Q2 		$3K Buy
101
+9
+10% +$265 ﹤0.01% 6168
2020
Q1 		$3K Buy
92
+25
+37% +$924 ﹤0.01% 6172
2019
Q4 		$3K Sell
67
-10
-13% -$210 ﹤0.01% 6472
2019
Q3 		$1K Buy
77
+10
+15% +$143 ﹤0.01% 6414
2019
Q2 		$1K Hold
67
– – ﹤0.01% 6682
2019
Q1 		$1K Hold
67
– – ﹤0.01% 6625
2018
Q4 		$1K Sell
67
-37
-36% -$1.74K ﹤0.01% 6552
2018
Q3 		$9K Buy
104
+37
+55% +$4.4K ﹤0.01% 6020
2018
Q2 		$11K Buy
+67
New +$11.3K ﹤0.01% 5783
2018
Q1 		– Sell
-3
Closed -$365 – 6382
2017
Q4 		$0 Sell
3
-117
-98% -$12.6K ﹤0.01% 6568
2017
Q3 		$16K Buy
120
+119
+11,900% +$14.5K ﹤0.01% 6065
2017
Q2 		$0 Sell
1
-107
-99% -$12.8K ﹤0.01% 6579
2017
Q1 		$13K Buy
108
+80
+286% +$9.44K ﹤0.01% 5833
2016
Q4 		$4K Buy
28
+15
+115% +$3.77K ﹤0.01% 6345
2016
Q3 		$3K Buy
+13
New +$1.59K ﹤0.01% 6083

Other funds holding CLSD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AWM
Apollon Wealth Management Mount Pleasant, South Carolina $8.23B AUM 30.88% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Royal Bank of Canada's CLSD Position: Q3 2025 in Review

Royal Bank of Canada sold out of Clearside Biomedical (CLSD) in Q3 2025, closing a stake of 93 shares — an estimated $1K sold.

Royal Bank of Canada first reported a position in CLSD in Q3 2016 and held it in 27 quarters. The position peaked at $39K in Q3 2023. 26 funds tracked by Wall St. Rank hold CLSD as of Q3 2025.

  • Royal Bank of Canada reported no remaining Clearside Biomedical position as of Q3 2025 after selling out during the quarter.
  • Royal Bank of Canada sold 93 Clearside Biomedical shares in Q3 2025, an estimated $1K.
  • Royal Bank of Canada first reported a position in Clearside Biomedical in Q3 2016 and held it in 27 quarters.
  • Royal Bank of Canada's Clearside Biomedical position peaked at $39K in Q3 2023.
  • 26 funds tracked by Wall St. Rank held Clearside Biomedical as of Q3 2025.

Based on Royal Bank of Canada's 13F filing for Q3 2025, filed 14 Nov 2025.